Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)

Summary

The main aim of this clinical trial is to assess the safety and tolerability of PN20 in adult patients with primary immune thrombocytopenia (ITP). The main questions it aims to answer are: * Is PN20 safe in these patients? * Could these patients potentially benefit from PN20 treatment? Participants will * Receive one subcutaneous injection of PN20 according to weight; * Visit the clinic for assessment.

Timeline

Start

2025-03-07

Primary completion

2026-02-27

Completion

2026-04-28

Drugs

Indications